Invex Therapeutics Ltd (ASX:IXC)

Market Cap	9.39M +64.5%
Revenue (ttm)	229.08K -81.1%
Net Income	-835.92K
EPS	-0.01
Shares Out	75.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,204
Average Volume	28,752
Open	0.1250
Previous Close	0.1250
Day's Range	0.1050 - 0.1250
52-Week Range	0.0590 - 0.1800
Beta	0.22
RSI	52.56
Earnings Date	Feb 5, 2026

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, A...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IXC

Financial Performance

In fiscal year 2025, Invex Therapeutics's revenue was 229,084, a decrease of -81.10% compared to the previous year's 1.21 million. Losses were -476,868, -70.95% less than in 2024.